Neuropathological measures of increased tau phosphorylation across the Down syndrome lifespan
By
Jesse R. Pascual
Isabel Rivera
Halyma Nguyen
Phong T. Ngo
Alan Hoang
Elizabeth J. Andrews
Jeremy Rouanet
Sierra T. Wright
Lorena Sordo
Julia Kofler
Milos D. Ikonomovic
Florence Lai
Mark Mapstone
Bradley T. Christian
Benjamin L. Handen
Ira T. Lott
Eric Doran
Christy L. Hom
Jordan Harp
Frederick Schmitt
Dana L. Tudorascu
Beau M. Ances
Michael Phelan
Lei Liu
Lisi Flores-Aguilar
Elizabeth Head
March 22, 2026
Clinical Scorecard: Assessing Tau Phosphorylation Changes Throughout the Lifespan in Individuals with Down Syndrome
At a Glance
Category Detail
Condition Alzheimer disease neuropathology in Down syndrome Key Mechanisms Amyloid beta accumulation and hyperphosphorylated tau (p-tau) pathology progression Target Population Individuals with Down syndrome across the lifespan Care Setting Neuropathological and biomarker research settings; potential clinical biomarker monitoring
Key Highlights
People with Down syndrome develop amyloid beta accumulation starting after age 30, with nearly universal Aβ and p-tau pathology by age 40. Tau pathology in Down syndrome follows a Braak staging pattern similar to late-onset Alzheimer disease but progresses more rapidly. Plasma and CSF p-tau biomarkers (pThr181, pThr217, pThr231) increase around age 39 in Down syndrome, paralleling autosomal dominant AD trajectories. Guideline-Based Recommendations
Diagnosis
Use cerebrospinal fluid and plasma p-tau biomarkers (pThr181, pThr217, pThr231) for early detection of AD pathology in Down syndrome. Employ neuroimaging (PET) to monitor amyloid beta accumulation starting in mid-30s. Management
Monitor cognitive status closely from age 40 onward due to high risk of mild cognitive impairment by age 54. Consider biomarker-guided approaches to track disease progression in Down syndrome. Monitoring & Follow-up
Regular assessment of plasma and CSF p-tau levels to detect and quantify tau pathology progression. Use immunohistochemical and digital pathology techniques in research to quantify p-tau burden in brain tissue. Risks
Rapid progression from amyloid beta accumulation to tau pathology within approximately five years in Down syndrome, faster than in late-onset AD. High prevalence of AD neuropathology by middle age in Down syndrome increases risk for cognitive decline. Patient & Prescribing Data
Individuals with Down syndrome aged 1 to 68 years, including those with and without AD neuropathology
Biomarker profiles of p-tau epitopes (pThr181, pThr217, pThr231) correlate with neuropathological burden and may inform timing of interventions
Clinical Best Practices
Exclude cases with mosaicism and partial trisomy when assessing neuropathology in Down syndrome. Balance study groups for sex, age, postmortem interval, and AD neuropathology presence to ensure robust comparisons. Use blinded, randomized immunohistochemical analysis with standardized image acquisition and quantification protocols to assess p-tau burden. References
